There is no assurance that this process will result in the completion of any specific transaction or outcome.
Our lead program and current focus is on the development of the fixed dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor ...
Vosevi can also be used to treat genotype 1a or 3 patients who previously received sofosbuvir without an NS5A inhibitor over a 12 week period. But the new launch isn't expected to reverse the ...
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the ...
PASADENA, Calif., Dec. 5, 2024 /PRNewswire/ -- AcuraStem, a patient-based biotechnology company pioneering the development of treatments for amyotrophic lateral sclerosis (ALS) and additional ...
Franchisee Matt Ridenour and his general manager, Kristen Vernon, are launching the in-home senior care franchise to serve the Woodland Hills and Thousand Oaks neighborhoods of L.A. LOS ANGELES ...
Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, White City Campus, Wood Lane, London W12 0BZ, U.K. Department of Chemistry, Imperial College London, Molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback